A systematic review of SARS-CoV-2 vaccine candidates

• Published in: Signal transduction and targeted therapy Vol. 5; no. 1; p. 237
• Main Authors: Dong, Yetian, Dai, Tong, Wei, Yujun, Zhang, Long, Zheng, Min, Zhou, Fangfang
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13-10-2020
• Subjects: 631/250/590; 631/326/590; Angiotensin-Converting Enzyme 2; Antibodies, Viral - biosynthesis; Betacoronavirus - drug effects; Betacoronavirus - immunology; Betacoronavirus - pathogenicity; Cancer Research; Cell Biology; Clinical Trials as Topic; Coronavirus Infections - immunology; Coronavirus Infections - prevention & control; Coronavirus Infections - virology; COVID-19; COVID-19 Vaccines; Gene Expression Regulation - drug effects; Humans; Immunity, Innate - drug effects; Immunization Schedule; Immunogenicity, Vaccine; Internal Medicine; Medicine; Medicine & Public Health; Middle East Respiratory Syndrome Coronavirus - drug effects; Middle East Respiratory Syndrome Coronavirus - immunology; Middle East Respiratory Syndrome Coronavirus - pathogenicity; Oncology; Pandemics - prevention & control; Pathology; Patient Safety; Peptidyl-Dipeptidase A - genetics; Peptidyl-Dipeptidase A - metabolism; Pneumonia, Viral - immunology; Pneumonia, Viral - prevention & control; Pneumonia, Viral - virology; Protein Binding; Receptors, Virus - antagonists & inhibitors; Receptors, Virus - genetics; Receptors, Virus - metabolism; Review; Review Article; SARS-CoV-2; Severe Acute Respiratory Syndrome - immunology; Severe Acute Respiratory Syndrome - prevention & control; Severe Acute Respiratory Syndrome - virology; Severe acute respiratory syndrome-related coronavirus - drug effects; Severe acute respiratory syndrome-related coronavirus - immunology; Severe acute respiratory syndrome-related coronavirus - pathogenicity; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - metabolism; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Subunit; Vaccines, Virus-Like Particle; Viral Vaccines - administration & dosage; Viral Vaccines - biosynthesis
• ISSN: 2059-3635; 2095-9907; 2059-3635
• DOI: 10.1038/s41392-020-00352-y

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the experimental and clinical data obtained from recent SARS-CoV-2 vaccines trials, and highlight certain potential safety issues that require consideration when developing vaccines. Furthermore, we summarize several strategies utilized in the development of vaccines against other infectious viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the aim of aiding in the design of effective therapeutic approaches against SARS-CoV-2.